Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma
RNA-seq (gene expression) · human · 39 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- CholangiocarcinomaThis series is part of our curated briefing on it.
- Samples
- 39 samples: 13 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE318391_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1418659 and SRA study SRP674594. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 39 samples.
How we read this: 13 replicated groups read from 39 sample titles; they account for 39 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9493625 HUCCT1_C1 HUCCT1_C
- GSM9493626 HUCCT1_C2 HUCCT1_C
- GSM9493627 HUCCT1_C3 HUCCT1_C
- GSM9493628 HUCCT1_T1 HUCCT1_T
- GSM9493629 HUCCT1_T2 HUCCT1_T
- GSM9493630 HUCCT1_T3 HUCCT1_T
- GSM9493631 KKU213A_C1 KKU213A_C
- GSM9493632 KKU213A_C2 KKU213A_C
- GSM9493633 KKU213A_C3 KKU213A_C
- GSM9493634 KKU213A_T1 KKU213A_T
- GSM9493635 KKU213A_T2 KKU213A_T
- GSM9493636 KKU213A_T3 KKU213A_T
- GSM9493637 KPCH_C1 KPCH_C
- GSM9493638 KPCH_T1 KPCH_T
- GSM9493639 KPCH_C2 KPCH_C
- GSM9493640 KPCH_T2 KPCH_T
- GSM9493641 KPCH_C3 KPCH_C
- GSM9493642 KPCH_T3 KPCH_T
- GSM9493643 iAKP_C1 iAKP_C
- GSM9493644 iAKP_C2 iAKP_C
- GSM9493645 iAKP_C3 iAKP_C
- GSM9493646 iAKP_T1 iAKP_T
- GSM9493647 iAKP_T2 iAKP_T
- GSM9493648 iAKP_T3 iAKP_T
- GSM9493649 hKP_R1 hKP
- GSM9493650 hKP_R2 hKP
- GSM9493651 hKP_R3 hKP
- GSM9493652 KPCH_972_R1 KPCH_972
- GSM9493653 KPCH_972_R2 KPCH_972
- GSM9493654 KPCH_972_R3 KPCH_972
- GSM9493655 KPCH_993_R1 KPCH_993
- GSM9493656 KPCH_993_R2 KPCH_993
- GSM9493657 KPCH_993_R3 KPCH_993
- GSM9493658 hKP_Parental_1 hKP_Parental
- GSM9493659 hKP_Parental_2 hKP_Parental
- GSM9493660 hKP_Parental_3 hKP_Parental
- GSM9493661 KPCH_Parental_1 KPCH_Parental
- GSM9493662 KPCH_Parental_2 KPCH_Parental
- GSM9493663 KPCH_Parental_3 KPCH_Parental
- GSE318388 Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma [Human_Abr24] 12 samples same disease briefing · shares ras-gtp, cholangiocarcinoma, anticancer, inhibition, activity
- GSE274024 NOX4/NOX1 dual inhibition in cholangiocarcinoma as an effective approach to target TGF-beta protumorigenic actions in cancer associated fibroblasts 45 samples same disease briefing · shares cholangiocarcinoma, inhibition
- GSE241735 FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma 30 samples same disease briefing · shares cholangiocarcinoma, inhibition
- GSE269494 Surufatinib increases cholangiocarcinoma cells radiosensitivity by anti-tumor proliferation and inhibition of macrophage M2 polarization 12 samples same disease briefing · shares cholangiocarcinoma, inhibition
- GSE231854 The heterogeneity analysis of hepatocellular carcinoma and combined hepatocellular cholangiocarcinoma 81 samples same disease briefing · shares cholangiocarcinoma
- GSE317889 Combined DNA and RNA profiling refines prognostic stratification independent of therapeutic actionability in cholangiocarcinoma 62 samples same disease briefing · shares cholangiocarcinoma
- GSE320081 Molecular and cellular consequences of tumor-autonomous IL-6 signaling in intrahepatic cholangiocarcinoma 36 samples same disease briefing · shares cholangiocarcinoma
- GSE235891 Identification of RNF213 as a potential suppressor of local invasion in intrahepatic cholangiocarcinoma 18 samples same disease briefing · shares cholangiocarcinoma
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.